Rationally designed bacterial consortia to treat chronic immune-mediated colitis and restore intestinal homeostasis

Daniel Lelie (), Akihiko Oka, Safiyh Taghavi, Junji Umeno, Ting-Jia Fan, Katherine E. Merrell, Sarah D. Watson, Lisa Ouellette, Bo Liu, Muyiwa Awoniyi, Yunjia Lai, Liang Chi, Kun Lu, Christopher S. Henry and R. Balfour Sartor
Additional contact information
Daniel Lelie: Gusto Global LLC
Akihiko Oka: University of North Carolina at Chapel Hill
Safiyh Taghavi: Gusto Global LLC
Junji Umeno: University of North Carolina at Chapel Hill
Ting-Jia Fan: Gusto Global LLC
Katherine E. Merrell: Gusto Global LLC
Sarah D. Watson: Gusto Global LLC
Lisa Ouellette: Gusto Global LLC
Bo Liu: University of North Carolina at Chapel Hill
Muyiwa Awoniyi: University of North Carolina at Chapel Hill
Yunjia Lai: University of North Carolina at Chapel Hill
Liang Chi: University of North Carolina at Chapel Hill
Kun Lu: University of North Carolina at Chapel Hill
Christopher S. Henry: Gusto Global LLC
R. Balfour Sartor: University of North Carolina at Chapel Hill

Nature Communications, 2021, vol. 12, issue 1, 1-17

Abstract: Abstract Environmental factors, mucosal permeability and defective immunoregulation drive overactive immunity to a subset of resident intestinal bacteria that mediate multiple inflammatory conditions. GUT-103 and GUT-108, live biotherapeutic products rationally designed to complement missing or underrepresented functions in the dysbiotic microbiome of IBD patients, address upstream targets, rather than targeting a single cytokine to block downstream inflammation responses. GUT-103, composed of 17 strains that synergistically provide protective and sustained engraftment in the IBD inflammatory environment, prevented and treated chronic immune-mediated colitis. Therapeutic application of GUT-108 reversed established colitis in a humanized chronic T cell-mediated mouse model. It decreased pathobionts while expanding resident protective bacteria; produced metabolites promoting mucosal healing and immunoregulatory responses; decreased inflammatory cytokines and Th-1 and Th-17 cells; and induced interleukin-10-producing colonic regulatory cells, and IL-10-independent homeostatic pathways. We propose GUT-108 for treating and preventing relapse for IBD and other inflammatory conditions characterized by unbalanced microbiota and mucosal permeability.

Date: 2021
References: Add references at CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
https://www.nature.com/articles/s41467-021-23460-x Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-23460-x

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-021-23460-x

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().